The Medical Letter on Drugs and Therapeutics
New Drugs for Multiple Sclerosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

In recent years, several new drugs have been approved by the FDA for use in multiple sclerosis (MS),1-4 and many others are in the pipeline. Most recently, teriflunomide (Aubagio – Genzyme) became the second oral drug to be approved by the FDA for treatment of relapsing forms of MS.

STANDARD TREATMENT — About 85% of patients with multiple sclerosis present with the relapsing-remitting form of the disease, and about half of them convert to secondary progressive MS within 10 to 20 years. Treatment usually includes various drugs for managing symptoms such as fatigue, depression and pain, and corticosteroids for acute exacerbations. Interferon beta and glatiramer acetate, which must be injected, are commonly used for first-line treatment of the disease. They can reduce clinical relapse rates by about 30% and decrease brain lesions seen on ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: New Drugs for Multiple Sclerosis
Article code: 1403a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian